Related Experiment Videos
Symptomatic treatment of acute infectious diarrhoea: loperamide versus placebo in a double-blind trial
Abstract:
One hundred and twelve patients with acute infectious diarrhoea were entered in a double-blind randomised study in order to compare loperamide with a placebo. Of 82 evaluable patients, 38 received loperamide and 44 placebo for a maximum of 5 days. There were no significant differences in the number of loose stools during the first day of treatment, in the total number of tablets taken or in the total duration of the period of diarrhoea between the two treatment groups. The loperamide-treated patients had significantly fewer loose stools during the observation period of 5 days than did the placebo treated patients, median five vs. seven, a difference of little clinical importance. Excretion of bacterial pathogens was followed weekly in 13 of the loperamide treated patients (median 35.5 days) and in 18 of the placebo treated patients (median 22.5 days). This difference in the duration of excretion was not significant.
Insights
Loperamide did not significantly reduce stool frequency on the first day of treatment for acute infectious diarrhea. While loperamide showed a slight reduction in loose stools over 5 days, it had little clinical importance and did not affect pathogen excretion duration.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Acute infectious diarrhea is a common condition requiring effective treatment.
- Loperamide is an antidiarrheal agent often used to manage symptoms.
Purpose of the Study:
- To compare the efficacy of loperamide versus placebo in patients with acute infectious diarrhea.
- To evaluate the impact of loperamide on stool frequency and duration of illness.
Main Methods:
- A double-blind, randomized study involving 112 patients with acute infectious diarrhea.
- 82 evaluable patients were treated with either loperamide or placebo for up to 5 days.
- Stool frequency, total tablets taken, and duration of diarrhea were recorded. Pathogen excretion was monitored weekly.
Main Results:
- No significant difference in stool frequency on day 1, total tablets, or overall diarrhea duration between groups.
- Loperamide group had fewer loose stools over 5 days (median 5 vs. 7), a difference of minor clinical significance.
- No significant difference in the duration of bacterial pathogen excretion between loperamide and placebo groups.
Conclusions:
- Loperamide demonstrated a statistically significant but clinically unimportant reduction in loose stools over 5 days compared to placebo.
- Loperamide did not significantly alter the duration of pathogen excretion in infectious diarrhea.
- Further research may be needed to establish the clinical utility of loperamide in specific infectious diarrhea contexts.